Several natural compounds are listed as inhibitors of transthyretin amyloidosis and neuroprotective agents [19], but, currently, there are only few TTR ligands approved or under investigation for the ATTR pharmacological therapy (Figure 1A). Here, TTR is linked to amyloidosis.